Cetuximab every-2-weeks versus standard weekly dosing administration schedule - supplementary material

Table S1. Studies evaluating cetuximab Q2W plus irinotecan in KRAS-unselected patients
Table S2. Studies evaluating cetuximab Q2W plus irinotecan in patients with (K)RAS wt mCRC
Table S3. Studies evaluating cetuximab Q2W plus triplet CT in patients with KRAS wt mCRC
Table S4. Studies evaluating cetuximab Q2W and Q1W plus intermittent Nordic FLOX* in patients with KRAS exon 2 wt mCRC
Table S5. Comparable safety with Q1W and Q2W dosing
Table S6. Grade 3/4 AEs in special categories*
Table S7. Studies evaluating cetuximab Q2W as first line for R/M SCCHN